U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H23N5O2S2
Molecular Weight 489.612
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-214662

SMILES

O=S(=O)(N1CC2=C(C=CC(=C2)C#N)N(CC3=CN=CN3)C[C@H]1CC4=CC=CC=C4)C5=CC=CS5

InChI

InChIKey=OLCWFLWEHWLBTO-HSZRJFAPSA-N
InChI=1S/C25H23N5O2S2/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22/h1-11,14,18,23H,12,15-17H2,(H,27,28)/t23-/m1/s1

HIDE SMILES / InChI

Molecular Formula C25H23N5O2S2
Molecular Weight 489.612
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Bristol-Myers Squibb developed BMS-214662 as potent and selective farnesyl transferase inhibitor with potent antitumor activity. BMS-214662 participated in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers. However, further information is not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.7 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Design, Synthesis and Evaluation of Novel 1-(Substituted Acetyl)-4-(10-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine-11-Ylidene)piperidines as Antitumor Agents and Farnesyl Protein Transferase Inhibitors.
2010 Sep
Patents

Patents

Sample Use Guides

Patients were treated every week as tolerated with i.v. paclitaxel (fixed dose, 80 mg/m(2)/wk) administered over 1 h followed by i.v. BMS-214662 (escalating doses, 80-245 mg/m(2)/wk) over 1 h starting 30 min after completion of paclitaxel.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:00:30 UTC 2023
Edited
by admin
on Fri Dec 15 18:00:30 UTC 2023
Record UNII
L2U9GFD244
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-214662
Code English
(R)-2,3,4,5-TETRAHYDRO-1-(1H-IMIDAZOL-4-YLMETHYL)-3-(PHENYLMETHYL)-4-(2-THIENYLSULFONYL)-1H-1,4-BENZODIAZEPINE-7-CARBONITRILE
Systematic Name English
1H-1,4-BENZODIAZEPINE-7-CARBONITRILE, 2,3,4,5-TETRAHYDRO-1-(1H-IMIDAZOL-4-YLMETHYL)-3-(PHENYLMETHYL)-4-(2-THIENYLSULFONYL)-, (R)-
Systematic Name English
BMS 214662
WHO-DD  
Code English
1H-1,4-BENZODIAZEPINE-7-CARBONITRILE, 2,3,4,5-TETRAHYDRO-1-(1H-IMIDAZOL-4-YLMETHYL)-3-(PHENYLMETHYL)-4-(2-THIENYLSULFONYL)-, (3R)-
Systematic Name English
BMS 214662 [WHO-DD]
Code English
7-CYANO-2,3,4,5-TETRAHYDRO-1-(1H-IMIDAZOL-4-YLMETHYL)-3-(PHENYLMETHYL)-4-(2-THIENYLSULFONYL)-1H-1,4-BENZODIAZEPINE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C2020
Created by admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
Code System Code Type Description
CHEBI
167655
Created by admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
PRIMARY
FDA UNII
L2U9GFD244
Created by admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
PRIMARY
CAS
195987-41-8
Created by admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
PRIMARY
NCI_THESAURUS
C1856
Created by admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
PRIMARY
EPA CompTox
DTXSID20173260
Created by admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
PRIMARY
PUBCHEM
448545
Created by admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
PRIMARY
DRUG BANK
DB12234
Created by admin on Fri Dec 15 18:00:30 UTC 2023 , Edited by admin on Fri Dec 15 18:00:30 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY